Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great find, Newtg!
The poster presentation is about 5 weeks out, and it's good to see that we will be represented on Sat, Dec 9th, at 6:30 pm.
"636. Myelodysplastic Syndromes – Basic and Translational: Poster I
Oral and Poster Abstracts"
https://ash.confex.com/ash/2023/webprogram/meeting.html
That's what happens when "vaccines" fail to prevent infection.
Regarding Novavax, "...the EMA had questions on the potency of the vaccine's latest version, and that it is seeking to ensure its characteristics will be the same across different production sites..."
https://www.reuters.com/business/healthcare-pharmaceuticals/eu-delays-approval-novavaxs-revised-covid-vaccine-ft-2023-10-15/
As far as finding new and evolving information, I think Novavax is going to figure prominently in our near-term and continuing success. I hope I can go from monitoring our progress by using a calendar, to measuring the time till our success with a watch.
That applies to counting down the time till other objectives are achieved, also, ones that management has told us about, such as aGvHD trial progress, approval to treat CMML, and even a covid EUA.
Positive news on any of the four catalysts above will lead to completing a 5th objective, enacting the recall of our loaned shares. We'll see if we announce a 5:1 forward stock split with this other news, or if that is delayed until we announce our re-listing on Nasdaq.
Bottom line is that Novavax is getting a lot of focus from my posts on X.
"Novavax's Updated COVID-19 Vaccine Now Approved in the EU
October 31, 2023...
"Today's approval of the only updated protein-based non-mRNA COVID-19 vaccine in the EU is an important milestone as the need for vaccination continues," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Novavax is working closely with national authorities to have our updated vaccine delivered and available in Europe in the coming weeks."
Novavax is working closely with EU member states that have requested doses through the advance purchase agreement to confirm timing of dose delivery on a country-by-country basis...
When added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant enhances the immune system response, making it broader and more durable...
Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined."
https://ir.novavax.com/press-releases/2023-10-31-Novavaxs-Updated-COVID-19-Vaccine-Now-Approved-in-the-EU
I'm interested to see if this approval leads to an announcement regarding an opportunity for lenz.
Regarding all of these SPNG-related posts, an early transcript between the bankruptcy judge and the trustee reflects their discussion about what to do with all the naked shorts, so the judge just decided not to order the required list of shareholders.
Subsequently, the trustee and the SEC entered into an agreement to deregister the shares. The judge sided with shareholders to rule against the settlement agreement.
I was able to subpoena the Electronic Blue Sheet trading records from FINRA, reflecting tens of millions of naked short sells everyday.
Ultimately, the Judge told me that he thought shareholders had a claim against the brokerages, but he couldn't see how naked shorts negatively impacted the company. I explained how it did, but not to his satisfaction. How a bankruptcy judge can sit on a seat in the EDNY, and not understand basic economics, should be surprising. But it's not.
The criminal court judge just sat on a motion I had filed, until she dismissed the motion when she found the company executives guilty.
Judge Denise Cote, who wrote the widely referenced SEC v Cavanagh decision, found several of those same defendants guilty of contempt of court, after I notified her of her defendants' participation in the SPNG case, despite being barred from such participation.
I'll contact Special Counsel John Durham about the SPNG case after we are successful here, complete with a short squeeze and authorizations and approvals.
These posts about SPNG should not be on the HGEN board. But they are, and as such, I wanted viewers to see that there was another side to the story.
You're more than welcomed to express your view.
I read that earlier this morning, Yooo. "America's Sweetheart" says that, "When the time is right, I will be sharing more information about my health issues and hope I can help others who may face the same battle as me. I love you all." All I know is that once management was alerted to her situation, she had a very fast recovery.
Yes.
I'm not talking about purchasing an expedite. A Priority Review Voucher could be awarded to us. How we use it could include selling it to another party.
Yes, it appears that Bluebird is selling their PRV for $103M. There is a chance that we could also be awarded a PRV, from Australia, or even a US PRV from the Medical Countermeasures Act I referenced previously. The bottom line is that we could once again see the exact amount of change in our daily share price, at exactly the same time that BLUE does. I call it Price Change Parity, and most here don't want to hear about it again. They will just marvel at how the XBI (?) chart matches the company chart like a mirror, and I guess they just think it happens by magic.
Are you somehow referring to the possible PRV? Sorry, I'm not following what you consider a 'cheap option.'
We have the possibility of also receiving a Priority Review Voucher, or two, so we will likely be able to watch for Price Change Parity with them again, going forward.
https://www.reuters.com/business/healthcare-pharmaceuticals/bluebird-bio-sell-sickle-cell-gene-therapy-fda-voucher-103-million-if-approved-2023-10-30/
When the company raises the curtain and reveals the second recall of their loaned shares, this one announced with either CMML approval, or news from Novavax, or a covid EUA, there will be an even greater response in share price than we saw previously. So I will re-enter my four highest-priced sells at $100, $150, $200, and $250 (as I indicated before), and I will try not to sell my other shares too cheaply. I have no doubt the Q's will be submitted, once the delay of the financial reports has served its purpose.
You have a very superficial view. You're hopelessly unable to understand a threat assessment, let alone contribute constructively to its development. Your $700K paper loss, matches a $700K profit target I have, based on selling just over 16% of my shares.
It's inconceivable to you that a delayed filing represents anything beyond either managerial "incompetence or fraud." There's no way you comprehend the strategic advantage management has gained by positioning the company where it is. Granted, with the historically negative context associated with a company being "kicked down" to the Expert Market, it isn't easy to see anything good about that, even if the move was intentional. Sorry, but sometimes truth can be difficult to understand, until the reasoning is revealed, as it will be soon. Hell, I hope it's today.
Nothing has caused me to question the truth of the reported safety and efficacy data of lenz, detailed in PR's referencing data that has been peer-reviewed by both Lancet and Thorax. Yet, you cast doubt, and possibly detract new investors, by your wondering " if anything that was claimed was true." And don't give me what the class action lawyers said again. I've made it abundantly clear that they based their case on data obtained in treating late-stage patients in the government-sponsored trial, just the opposite of the company's trial of early-stage patients.
Of course, a good time to find out what "monstrous gains" look like might be on Halloween, or in Halloween week.
I can't disconnect knowledge of our lenz/vaccine/anti-viral cocktail patent, from the EU's needing more time to study the efficacy Novavax is reporting. The already authorized/approved vaccine only needed to be reformulated to treat the XBB variant for the 2023-2024 vaccine year. Procedural.
The FDA permitted the updated vaccine without issue.
What caused the EU to focus increased attention on the reported Novavax efficacy? Am I right about Novavax studying the effect of using lenz as an adjuvant with their vaccine?
I don't know, Yooo.
But management patented that cocktail for a reason, actually, for being administered with a traditional covid vaccine. The EU represents a 200M dose market for Novavax, compared to the 8M dose US market. Makes sense to target the largest market.
All I know is that when we are able to re-enter sell orders, I'm going to refrain from pre-entering low-priced sell orders. I want to see how the market reacts to the recall of our loaned shares, and watch for news regarding covid and CMML authorizations or approvals.
"Safe COVID-19 vaccines for Europeans
Company.... Type of vaccine.... Number of doses (needed per person).... Number of doses (secured)....Status
BioNTech and Pfizer mRNA 2 doses 2.4 billion* Approved
Moderna mRNA 2 doses 460 million Approved
AstraZeneca adenovirus 2 doses 400 million Approved
Johnson & Johnson/Janssen Pharmaceuticals adenovirus 1 dose 400 million Approved
Sanofi-GSK protein 2 doses 300 million Approved
HIPRA Human Health protein 1 dose 250 million Approved
Novavax protein 2 doses 200 million** Approved
Valneva inactivated virus vaccine 1.2 million Approved
*option to purchase 900 million doses, **option to purchase 100 million doses"
"EU grants full marketing authorisation for Novavax’s Covid-19 vaccine
The EMA has granted Novavax’s Covid-19 vaccine a full marketing authorisation, based on Phase III trial data"
.https://www.pharmaceutical-technology.com/news/eu-grants-full-marketing-authorisation-novavax-covid-19-vaccine/
Akosua Mireku
July 7, 2023"
https://commission.europa.eu/strategy-and-policy/coronavirus-response/safe-covid-19-vaccines-europeans_en
"EU delays approval of Novavax's revised COVID vaccine
Reuters
October 15, 202311:36 AM CDTUpdated 14 days ago
The Financial Times, which first reported the news, said the EMA had questions on the potency of the vaccine's latest version, and that it is seeking to ensure its characteristics will be the same across different production sites...EMA director Emer Cooke said in September that it expected to decide on the use of the vaccine this month. The agency is expected to give its approval within four weeks, according to the FT report."
https://www.reuters.com/business/healthcare-pharmaceuticals/eu-delays-approval-novavaxs-revised-covid-vaccine-ft-2023-10-15/
Much greater acceptance of traditional covid vaccines in Europe than in the US and UK. Evidently, the EU is surprised by the reported efficacy data. Might that be due to the use of lenz as an adjuvant? And this doesn't include any discussion of an opportunity with Janssen.
It's not one penny of profit to company insiders, if these shares were just transferred from one control account to a nominee account. The shares would still be for the beneficial ownership of the company.
We're going to see a stock-for-stock agreement with a business combination or merger partner. That would have to mean that the company beneficially owns the shares being transferred.
That same poster asked the same question some months ago. I spent hours trying to find him the post that I had copied and pasted the source data into, since we can no longer access the data source, and it's changed, anyway.
I'm glad to see that you were aware of MLR's disease progression, and comeback. I just saw a picture of her at 55 years old, with a beautiful smile, when the news broke that she was given days to live, and felt compelled to ask management to help her, if they could.
But, I would not put it past our management to have recommended toci or gohibic to a patient that seriously ill, if they weren't confident lenz could be successful. If that happened, I would still credit management for their help.
However, if lenz really did help her survive pneumonia, I saw nothing saying that it was covid pneumonia. So I would like to see the case study. It wouldn't even need to include her name.
But you raise a deeper question that I have often wondered about. I think Mayo Clinic, as well as management, could have thousands of compassionate use outcomes, for many others like MLR. That data would also be capable of providing covid reinfection rates for those lenz-treated patients, which is probably the one thing I have long asked for without a reply from management.
But, yes, MLR could potentially be a real and lovable star in a Humanigen lenz promotion.
Good friend, my post wasn't as tight as I would have liked. I just used it to illustrate my point, that being, that our perch on the EM has strategic value, as I've surmised, and I just get so tired of management getting constantly attacked by people who have no appreciation for why things are as they are. These are good people, as we have seen when it came to doing all they could, on their end, to getting you compassionate use for lenz. In that regard, I had asked them, via message board, if they thought Mary Lou Retton might be a candidate for lenz, also. I don't know how that turned out, I'd like to see a case study on it, but a post about her being discharged from the hospitalized, when just days before she was on her death bed, is one that stays highlighted on the company's X board. I hope that means that she was administered lenz. But think about it. That would mean that management recognized my post, resulting in Mary Lou's survival. It gives me hope that, since I couldn't get lenz for my wife, maybe I at least had a small role in Mary Lou getting it.
Regardless, lenz is capable of saving millions of lives, and I hope that we get authorized or approved to do that.
I can always count on you to require additional explanation in order to understand what I'm trying to say.
The action taken involved the acquisition of TeraImmune. The former, and now current auditing firm that Baudax has engaged, identified a,"... material weakness related to the implementation of purchase price accounting principles related to the acquisition of TeraImmune, Inc. The material weakness identified did not result in the restatement of any previously reported financial statements or any related financial disclosure, nor did management believe that it had any effect on the accuracy of the Company’s financial statements for the reporting period ended June 30, 2023. This reportable event was discussed among the Company’s management, the Audit Committee, and EisnerAmper. EisnerAmper has been authorized by the Company to respond fully to the inquiries of KPMG, the successor accountant, concerning this reportable event."
https://www.sec.gov/ix?doc=/Archives/edgar/data/1780097/000119312523262285/d564363d8k.htm
You may recall that Black Horse filed an amended 13G stemming from an equity purchase of Baudax shares the day they acquired TeraImmune.
https://www.sec.gov/Archives/edgar/data/1293310/000101359423000819/0001013594-23-000819-index.htm
So the issue is, if there is a problem with the purchase price accounting principles by Baudax, might that problem extend to Black Horse?
An issue with SpongeTech's auditing firm caused the Public Company Accounting Oversight Board (PCAOB) to order an audit every 10-K and 10-Q for the past year (and it may have even been 2 years, I can't recall specifically). Expensive and time consuming, especially when the CEO used his suit pockets to file things in.
I also recognized that I did not see enough information to conclude that the Baudax transaction was related to us, or just to Black Horse. I just concluded that it was a Humanigen transaction exercised through our financing arm. I also said that I could not keep up with the former Baudax controller, and the way she structured transactions through multiple merger-subs.
The thing is, I don't think Humanigen has claimed the transaction yet, so our second quarter 10-Q may be clean. From the Expert Market, we can submit our Q2 and Q3 filings, with news, and with stock transaction notifications, without getting bogged down in this mess.
How abhorrent to find it necessary to speak about defensive measures, such as going to the Expert Market to avoid the regulatory minefield of being on a trading venue, when one hour earlier, I questioned the possibility of lenz proving to be a cure for covid and certain cancers.
But, that is our reality. It's a reality made even worse by shareholders who fault management for the strategic positioning of the company on the Expert Market, and they don't even try to understand why management would this, not even when reason is before them.
In my opinion, the only material weakness or reportable event relevant to us has been our negligently-delayed authorization from the FDA and NIH/NIAID, which by now could have caused millions of preventable deaths worldwide, since our EUA application was submitted.
Nevertheless, I think management's strategic positioning of the company will prove successful, and will enable the use of lenzilumab to help stamp out covid and certain cancers. You would think health regulators would want that.
I did some reviewing of my older posts.
On May 8th, I commented, when we were trading in the $0.17 range, "Why have I started to think my shares are going to be worth $0.034, and that I won't be unhappy about that?"
On May 9th, I saw the float and OS projection indicating that management could be looking at a 5:1 FORWARD stock split.
"Just the opposite of a strategy I would have anticipated...again, if I'm right."
The OS and float numbers were obtained by following the Ihub data matrix. Those details have since been eliminated for HGEN's data.
https://ih.advfn.com/stock-market/USOTC/humanigen-ce-HGEN/chart
Subsequent to those posts, I copied and pasted that information in another post.
It's in my posting history, along with a stated OS of 595,400,675.
What now appears to be bogus information, Yooo?
If our float is 229M shares, as it may be, then there are 110M more shares in the market, than the company issued. I think the company has purchased as many shares as they have issued, and those extra 110M shares represent the number of shares the company loaned. Those are the shares that will have to be purchased if the company recalls their loaned shares, as I fully expect them to do.
Well, Yooo, the fortunate thing for you is that you continued to buy during your prolonged litany of crying foul. As long as you have been so heavily invested here, it would have been nice if this had proven to be a learning experience for you. But at least you'll be rewarded for holding your shares.
Very relieved to get a response from you, Tank, and very glad to hear your answer. Thank you!
You haven't seen yet what "monstrous gains" look like.
I've been speculating about how our catalysts might be executed in association with our two uplistings.
But, now I'm wondering what might happen if management recalled their loaned shares while we are still on the Expert Market.
I hope we get resolution soon, like tomorrow. Imagining the carnage and chaos that possibility could wreak on short sellers is hard to imagine for more than just a day.
I'm not sure that I understand this.
Good to see you, dlog. Are you still with us?
Personally, I think if management had filed the 2nd quarter 10-Q, then Baudax would not be the only company in our trio filing an 8-K such as the one they filed today.
Money-hungry, small-cap biotechs, on the precipice of huge news, are prime targets for destruction, before their success can be realized. Moving us to the Expert Market (getting us out of the minefield), insulates us, to an extent, against the same fate Baudax has found itself in today.
What major fraud? Management has disclosed their financial constraints, although they may not yet have revealed their financial relief.
And the clinical trial data is verified in multiple peer-reviews.
I think they, and perhaps the Philippines, may announce approval when Australia does. Do Asia-Pacific all at once. But that's just a guess in answer to a very good question. I hope Bob Atwill is still with us.
I think Baudax would be well-served by engaging KPMG to audit not only the previous 10-K, but the quarterly reports for Q1 and Q2 as well, even though the Q's don't normally require auditing. The Q2 quarterly report would include our investment with them. This may stave off any PCAOB inquiry, forcing the audit of the quarterly filings, which is a route I have previously seen taken.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1780097/000119312523262285/d564363d8k.htm
I really hope that we can conclude this week as I believe management is planning to do. I am really looking forward to the recall of the company's loaned shares, and the submission of our Q2 and Q3 filings.
Will lenz prove to be a cure for covid, AND for myeloid-driven cancer?
Max Lugavere is somebody I might like to learn more about. My wife, who died three years ago this month, had cancer and was also placed in covid wings twice, as I recall, but her cause of death was senile degeneration of the brain, which relates to what Max discussed so well. Max mentioned antibodies in relation to causing brain swelling, and that is just the opposite of my thinking.
"Mary Lou Retton released from hospital, recovering at home after pneumonia battle"
https://www.yahoo.com/sports/mary-lou-retton-released-from-hospital-recovering-at-home-after-pneumonia-battle-194211248.html
I hope we hear more about this, if applicable.
Some time ago, I saw data reflecting a float of 229M shares. I think management owns all the shares they have issued, and have loaned the 110M of those shares in excess of our OS. Those 110M loaned shares are what I expect management to recall, forcing a huge short squeeze.